Clinical Trials Logo

Clinical Trial Summary

This study evaluates the dosage of perioperative cefuroxime for obese patients. Dosage was increased if the BMI was over 30kg/m*m and as well over 50kg/m*m. Drug levels were measured in blood and tissue.


Clinical Trial Description

Cefuroxime is an often used antibiotic for surgery antibiotic prophylaxis to avoid surgical wound infection. In this study the dosage of cefuroxime was adjusted to the BMI:

less than 30kg/m*m: 1,5g 31-50kg/m*m: 3,0g more than 50kg/m*m: 4,5g

Cefuroxime was applicated 30 to 60 minutes before the begin of surgery. Drug Levels in blood and fat tissue were measured at skin cut (30-60 minutes after application of Cefuroxime), 45 minutes after skin cut (75-105 minutes after minutes after application of Cefuroxime) and at the end of surgery (up to 150 minutes after application of Cefuroxime) .

The hypothesis of this study is that adequate drug levels are reached in all groups. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03141476
Study type Interventional
Source Universitätsklinikum Hamburg-Eppendorf
Contact
Status Completed
Phase Phase 4
Start date March 1, 2017
Completion date December 12, 2017

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05162001 - Body Weight Response With Disulfiram in Humans Early Phase 1
Recruiting NCT05176626 - Long-term Effectiveness of the Antiobesity Medication Phentermine Phase 4
Completed NCT04730375 - Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients Phase 2
Recruiting NCT03593668 - Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control Phase 4
Recruiting NCT05087342 - Latino Semaglutide Study Phase 3
Recruiting NCT06390501 - The Effect of Weekly Semaglutide Treatment on Energy Expenditure N/A